MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$20,165K
EPS
-$0.32
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development (including related party amounts of 0, 230, 72 and 458, respectively)
16,388
14,379
13,639*
14,589
General and administrative (including related party amounts of 60, 131, 145 and 265, respectively)
5,789
5,327
4,509*
4,722
Total operating expenses
22,177
19,706
18,147
19,311
Loss from operations
-22,177
-19,706
-18,147*
-19,311
Interest income
2,012
2,070
2,475*
2,314
Net loss
-20,165
-17,636
-15,672
-16,997
Basic EPS
-0.32
-0.29
-0.269
-0.3
Diluted EPS
-0.32
-0.29
-0.269
-0.3
Basic Average Shares
62,505,340
61,434,457
58,180,189
56,950,999
Diluted Average Shares
62,505,340
61,434,457
58,180,189
56,950,999
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$20,165K
(-5.67%↓ Y/Y)
Interest income
$2,012K
(-19.07%↓ Y/Y)
Loss from operations
-$22,177K
(-2.82%↓ Y/Y)
Total operating
expenses
$22,177K
(2.82%↑ Y/Y)
Research and development
(including related party...
$16,388K
(4.13%↑ Y/Y)
General and
administrative (including...
$5,789K
(-0.72%↓ Y/Y)
Buy us a coffee
Design Therapeutics, Inc. (DSGN)
Design Therapeutics, Inc. (DSGN)